Same source more quotes ...
Japan reimbursement is about $195.000 per patient ,Silviu said, noting that Japan generally reimbursement is at about 60% compared to the U.S. The product has " outperformed our expectations " he said the uptake indicated that the clinicians have no problems in using *Gvhd treatment and adopting to a disease that doesn't haveother alternatives ....Roughly 12,000 bone marrow transplants are conducted each year in the U.S.and a out half will develop GVHD ...Also Japan data will support the BLA ......
On RA Silviu said , the stem cell therapy is seeing " consistentcy in terms of multiple indications and durable outcomes in RA and disc diseases"....Cheers
Ann: Day 180 Survival Outcomes In aGvHD Phase 3 Trial, page-72
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 75212 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |